Just before the 23andMe SPAC deal closed, the stock belonging to its merger ... giving investors the impression it is a risk-free investment. Some companies do not find appropriate acquisition targets ...

Leaders of the House Committee on Energy and Commerce said they are investigating how 23andMe’s bankruptcy might affect ...

Me on Sunday filed for bankruptcy in the U.S. after struggling with weak demand for its ancestry testing kits and a 2023 data ...

Today the market is a SPAC graveyard—with genetics testing startup 23andMe the latest casualty after declaring Chapter 11 bankruptcy late Sunday night. According to new data from the financial ...

GlaxoSmithKline also made a $300 million equity investment in 23andMe. When 23andMe went public ... if it shows that they have or are at high risk of developing a genetic disease or disorder.

The company's bankruptcy has spotlighted the vulnerability of private consumer genetic testing data.

Genetic analysis company 23andMe (ME) announced this week it's declaring bankruptcy and pursuing a sale, leading many customers to pursue deleting their data from the company. 23andMe was founded ...

23andMe is going bankrupt — underscoring the great risks of investing in many of the companies that have gone public via mergers with special-purpose acquisition corporations. When companies opt ...

23andMe bankruptcy underscores the risk of investing in most SPACs. - MarketWatch photo illustration/iStockphoto 23andMe is going bankrupt — underscoring the great ...

Just before the 23andMe SPAC deal closed ... giving investors the impression it is a risk-free investment. Some companies do not find appropriate acquisition targets and have to redeem the ...